Recently, clinical trials of immuno-adjuvants including interleukin-7 (IL-7), granulocyte macrophage colony stimulating factor (GM-CSF), thymosin α1, and the checkpoint inhibitors, anti-programmed cell death protein 1 (α-PD-1) and anti-programmed cell death ligand 1 (α-PD-L1), have been initiated in sepsis [14]. This evidence concerns the gene CSF2 and Sepsis.